Travere Therapeutics (NASDAQ:TVTX) said it presented additional data from two Phase 3 studies for its drug Filspari that demonstrated the drug has potential in preserving kidney function and delaying kidney failure in patients with IgA nephropathy and focal segmental glomerulosclerosis, or FSGS.
The company said it presented the data the American Society of Nephrology Kidney Week 2023. The data was also published in The Lancet and The New England Journal of Medicine.
Shares of Travere were up 6% in afternoon trading Friday.
Filspari, also known as sparsentan, is available in the US under accelerated approval. The product is indicated to reduce proteinuria in adults with IgA nephropathy, also known as Berger’s disease, at risk for rapid disease progression.
Travere stock climbs 6% amid two medical meeting presentations
